Sagent Names Former Teva Executive as CEO

From DCAT Value Chain Insights (VCI)

By People On The Move posted 08-04-2015 13:16


Sagent Pharmaceuticals, Inc. a specialty pharmaceutical company with a specific emphasis on the injectables market, has named Allan Oberman as chief executive officer (CEO) and a member of the board of directors, effective immediately upon receipt of a US work visa.

Mr. Oberman most recently served as president and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd., from November 2012 until December 2014. Prior to that, Oberman held a number of senior roles with Teva since joining the company in 2000, including president of EMIA (Eastern Europe, Middle East, Israel and Africa), chief operating officer of The Teva International Group, and president and CEO of Teva Canada. Prior to joining Teva Pharmaceutical Industries Ltd., Allan was the president of Best Foods Canada Inc.

He also served as the vice chairman of the Canadian Generic Pharmaceutical Association (CGPA) from 2003 to 2007, chairman of CGPA in 2007 and 2008, and vice chairman of the US Generic Pharmaceutical Association (GPhA) in 2014.

Source: Sagent Pharmaceuticals


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription